Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2020 08:25 ET | Source: AC Immune SA

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

Grant from the ‘EU Joint Programme – Neurodegenerative Disease Research’ (JPND) provides €1.45M in funding for the program AC Immune’s proprietary Morphomer™ platform continues accelerating...
September 23, 2020 07:00 ET | Source: AC Immune SA

AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease

Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study; the primary safety endpoint was met Multiple other...
September 11, 2020 07:00 ET | Source: AC Immune SA

AC Immune to Showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference

LAUSANNE, Switzerland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
August 05, 2020 07:00 ET | Source: AC Immune SA

AC Immune Reports Q2 2020 Financial Results and Provides Business Update

Substantial progress achieved across three anti-Tau clinical development programs; all clinical and preclinical programs remain on track to generate value in the second half of 2020Top line Phase 2...
August 03, 2020 07:00 ET | Source: AC Immune SA

AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration

First-in-class TDP-43 antibody developed using SurpraAntigen™ platform The only TDP-43 antibody with reported in vivo activity LAUSANNE, Switzerland, Aug. 03, 2020 (GLOBE NEWSWIRE) --...
July 30, 2020 07:55 ET | Source: AC Immune SA

AC Immune Wins Prestigious Award to Develop a “Game-Changing” Parkinson’s Diagnostic Tool

AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging CompetitionThe award follows compelling preclinical results presented...
July 28, 2020 07:00 ET | Source: AC Immune SA

AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent

Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio Oral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer™ platform...
July 23, 2020 07:00 ET | Source: AC Immune SA

AC Immune to Present Advances in Two of the Company’s World Leading Programs at the Upcoming Alzheimer’s Association International Conference

LAUSANNE, Switzerland, July 23, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative...
July 16, 2020 07:00 ET | Source: AC Immune SA

AC Immune Advances phospho-Tau Alzheimer’s Vaccine in Phase 1b/2a Study

Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study ACI-35.030 is a clinical stage vaccine generated with the proprietary...
July 07, 2020 09:00 ET | Source: AC Immune SA

Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy

BERLIN and LAUSANNE, Switzerland, July 07, 2020 (GLOBE NEWSWIRE) -- Life Molecular Imaging and AC Immune SA (NASDAQ: ACIU) announce the publication of clinical data of the investigational...